nj

NANETS Regional NET Education: The Multidisciplinary Management of NET Cancers

CME/CE Certified Activity
Saturday, September 15, 2018
7:30am – 4:00pm 

REGISTER HERE 

Location

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901

Parking is available in the Gateway Garage, 7 Wall Street (at Easton Ave.), New Brunswick, NJ 08901 located at the New Brunswick Train Station and one block from the Rutgers Cancer Institute. The prevailing daily rates apply. Rutgers and hospital employees should park in their assigned parking areas.  For additional information, visit http://www.njnbpa.org/parking-locator/

 

Providers

Jointly Provided by Rutgers Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences and North American Neuroendocrine Tumor Society.

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors
  • Evaluate the latest diagnostic and treatment options for patients with carotid artery stenosis

Program

7:30am - 8:00am Registration & Breakfast

8:00am - 8:05am Welcome & Opening Remarks - Usha Malhotra, MD, Rutgers Cancer Institute of New Jersey

8:05am - 9:30am Overview of Neuroendocrine Tumors - Moderator: James Howe, MD, University of Iowa

  • Background, Epidemiology, NET Subcategories/Classification, Outcomes - Renuka Iyer, MD, Roswell Park Cancer Institute
  • Pathology and Molecular Characterization NET Staging, High Grade vs. Low/Intermediate Grade, Molecular Characterization - Sumi Thomas, MD, Rutgers Robert Wood Johnson Medical School
  • NETs in Setting of MEN/VHL - Steven Libutti, MD, FACS, Rutgers Cancer Institute of New Jersey
  • Panel Question and Answer

9:30am - 10:25am Diagnosis of NETs - Moderator: James Yao, MD, MD Anderson Cancer Center

  • Role of Radiology and Nuclear Medicine - Imaging Modalities in NETs - Murray Becker, MD, Rutgers Robert Wood Johnson Medical School
  • Endoscopic Assessment and Management - Amy Tyberg, MD, Rutgers Robert Wood Johnson Medical School
  • Obstacles in Diagnosis: Panel Discussion/Question and Answer

10:25am - 10:50am Break

10:50am - 12:10pm Surgical Management of NETs - Moderators: Amanda M. Laird, MD, FACS, DABS, Rutgers Cancer Institute of New Jersey and Steven Libutti, MD, FACS, Rutgers Cancer Institute of New Jersey

  • “Gastric Carcinoid” and Surgical Recommendations - Russell C. Langan, MD, Saint Barnabas Medical Center
  • Small Bowel and Mesenteric Nodal Mets without Bowel Obstructions/PNETs - Miral Sadaria Grandhi, MD, Rutgers Cancer Institute of New Jersey
  • Role for Surgery with Liver Metastases/IntraOp Management Carcinoid Crisis - James Howe, MD, University of Iowa
  • Panel Question and Answer

12:10pm - 1:30pm Lunch Symposium - Moderator: Michael Nissenblatt, MD, CJOC Division of RCCA

  • I Think I Have ”Carcinoid Syndrome” - Michael Nissenblatt, MD, CJOC Division of RCCA
  • Case Presentations
  • Panel Question and Answer

1:30pm - 3:00pm Medical Management of NETs - Moderator: Howard S. Hochster, MD, Rutgers Robert Wood Johnson Medical School

  • Overview of Targeted and Cytotoxic Therapies and Management of Grade 3 NETs - James Yao, MD, MD Anderson Cancer Center
  • Peptide Receptor Radionuclide Therapy (PRRT) and Clinical Trials - Jeffery Kempf, MD, Rutgers Robert Wood Johnson Medical School
  • Panel: Question and Answer

3:00pm - 3:15pm Break 

3:15pm - 3:45pm Loco-Regional Therapy Moderator: Jeffery Kempf, MD, Rutgers Robert Wood Johnson Medical School

  • RFA and TACE - John Nosher, MD, Rutgers Robert Wood Johnson Medical School
  • Radio-Embolization and External Beam Radiation - Laura Bond, MD, Rutgers Cancer Institute of New Jersey
  • Panel Question and Answer

3:45pm Closing Remarks - Usha Malhotra, MD, Rutgers Cancer Institute of New Jersey

4:00pm Adjourn

Continuing Education Credit

 joint provider image

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and North American Neuroendocrine Tumor Society. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

PHYSICIANS

Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

This activity is awarded 7 contact hours. (60 minute CH) Nurses should only claim those contact hours actually spent participating in the activity.

PHARMACISTS

This knowledge-based activity qualifies for 7 contact hours of continuing pharmacy education credit. Pharmacists should only claim those contact hours actually spent participating in the activity.

Pharmacists’ NABP e-Profile ID and date of birth will be collected at the conclusion of the program. CPE credit will be processed after the program evaluation has closed to participants, which will be three to four weeks following the activity date.

PHYSICIAN ASSISTANTS

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7 Category 1 credits for completing this activity.

Method of Participation

In order to meet the learning objectives and receive continuing education credit for this activity, participants are required to check in at the registration desk, attend the activity, and complete the online evaluation form at the conclusion of the activity. A letter certifying attendance and credit verification will be mailed to participants upon completion of the online evaluation survey.

Registration

Online registration available.
In-person registration available onsite on day of program and will be accommodated on a space-available basis

Registration fee:
$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy: A full refund will be made if registration is canceled, in writing, on or before September 10, 2018. On or after September 10, 2018, no refund will be made.

Rutgers Biomedical and Health Sciences and North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is cancelled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.